Lanean...
A systematic review and network meta-analysis of post-imatinib therapy in advanced gastrointestinal stromal tumour
BACKGROUND: The standard first-line systemic therapy for advanced gastrointestinal stromal tumour (gist) is imatinib. However, most gists develop imatinib resistance, highlighting the need for new agents in the imatinib-refractory setting. Currently, no randomized studies have directly compared the...
Gorde:
| Argitaratua izan da: | Curr Oncol |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Multimed Inc.
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5736493/ https://ncbi.nlm.nih.gov/pubmed/29270063 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.24.3463 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|